Clinical trials: Gemcitabine
Intrahepatic Cholangiocarcinoma (Icc)
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and…
- Trial name
- RAINBOW (NCT07691515)
- Testing
- Gemcitabine, Cisplatin, Tislelizumab
- Where
- 21 sites in China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Cancer Hospital
Intrahepatic Cholangiocarcinoma
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated…
- Trial name
- NCT04891289
- Testing
- Gemcitabine, Oxaliplatin, Dexamethasone
- Where
- 11 sites in United States, Netherlands
- Volunteers
- 164 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005991
- Testing
- gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00281996
- Testing
- Gemcitabine, Imatinib mesylate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwestern University
Lung Cancer
Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00022646
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 22 sites in United States
- Volunteers
- 157 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Neoplasms, Pancreatic Cancer
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Adenocarcinoma
- Trial name
- NCT01161186
- Testing
- nab-paclitaxel, gemcitabine, capecitabine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Testicular Cancer
Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
Study Objectives: Primary objective The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with germ cell tumours previously…
- Trial name
- NCT00531687
- Testing
- Paclitaxel, Cisplatin, Gemcitabine
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02181218
- Testing
- Romidepsin, Gemcitabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Sarcoma
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gemcitabine with docetaxel may kill more tumor cells.
- Trial name
- NCT00073983
- Testing
- filgrastim, pegfilgrastim, docetaxel
- Volunteers
- 54 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the…
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-103 (NCT03288545)
- Testing
- enfortumab vedotin (EV), pembrolizumab, cisplatin
- Where
- 106 sites in United States, Canada and 4 more
- Volunteers
- 348 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Renal Cell Carcinoma
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
Primary Objective: To determine the clinical activity of Pemetrexed + Gemcitabine in non-clear cell renal cell cancer (RCC). Clinical activity will take into account response rate and progression free survival (PFS).
- Trial name
- NCT00491075
- Testing
- Pemetrexed, Gemcitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Pancreatic Cancer
Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients
The aim of this study is to evaluate the efficacy of sequential treatment (Gabrinox) comprising Gembrax regimen (Gemcitabine -Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) compared to folfirinox…
- Trial name
- GABRINOX2 (NCT05065801)
- Testing
- GEMBRAX/FOLFIRINOX Arm A, FOLFIRINOX Arm B
- Where
- 8 sites in France
- Volunteers
- 162 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Pancreatic Cancer
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
Study Hypothesis: To estimate time to recurrence in pancreatic cancer patients treated with adjuvant erlotinib and gemcitabine. Combination therapy will be given for 4 months followed by single agent erlotinib for a total of 12…
- Trial name
- NCT00336700
- Testing
- Gemcitabine, Erlotinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert J. Zeh, III MD, FACS
Metastatic Pancreatic Adenocarcinoma
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Gemcitabine and nab-paclitaxel is a standard regimen (NCCN, Category 1) for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). However, further improvement in treatment is needed.
- Trial name
- NCT02562898
- Testing
- Ibrutinib, Paclitaxel, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Margaret Tempero
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma
- Trial name
- NCT05733000
- Testing
- Biospecimen Collection, Computed Tomography, Devimistat
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Small Cell Lung Cancer
G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients
The purpose of this study is to describe the activity and toxicity of gemcitabine combined with four different drugs (carboplatin or cisplatin or etoposide or vinorelbine) as first line treatment of elderly patients with…
- Trial name
- G-Step (NCT00401609)
- Testing
- gemcitabine, vinorelbine, cisplatin
- Where
- 21 sites in Italy
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute, Naples
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
Gemcitabine plus cisplatin (GC) is more effective than fluorouracil plus cisplatin in the treatment of recurrent or metastatic NPC (R/M-NPC). GC is the standard first-line chemotherapy regimen for this population.
- Trial name
- NCT03639467
- Testing
- Anlotinib plus gemcitabine/cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Biliary Tract Cancer
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Pemetrexed in combination with erlotinib as a salvage treatment in patients with metastatic biliary tract cancer (BTC) who failed gemcitabine containing chemotherapy
- Trial name
- NCT03110484
- Testing
- Pemetrexed 500 MG, Erlotinib
- Where
- 2 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Samsung Medical Center
Primary Pulmonary Lymphoepithelioma-like Carcinoma, Lung Cancer
Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma
The trial was designed to explore the safety and efficacy of sintilimab combined with gemcitabine and carboplatin in the treatment of advanced LELC.
- Trial name
- NCT04312204
- Testing
- Sintilimab combined with Gemcitabine and Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhou Chengzhi
Pancreatic Cancer
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
The primary objective is to confirm clinical safety and feasibility of combining the antigen-loaded Dendritic Cell (DC) vaccine with chemotherapy including folinic acid, oxaliplatin, irinotecan and 5-Fluorouracil (5FU)…
- Trial name
- PancVax (NCT02548169)
- Testing
- DC Vaccine + Standard of Care Chemotherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Baylor Research Institute